MNOV MediciNova Inc.

-0.4  -4%
Previous Close 8.93
Open 8.9
Price To Book 4.64
Market Cap 350830993
Shares 41,129,073
Volume 211,235
Short Ratio 29.53
Av. Daily Volume 114,847

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b top-line data released October 28, 2017 at Joint ECTRIMS – ACTRIMS meeting. Primary endpoint met.
Progressive multiple sclerosis (progressive MS)
Phase 2 abstract presented at EASL April 13, 2018. Noted April 2, 2018 that trial has been terminated early due meeting one of two primary endpoints (data from second endpoint of cholesterol efflux capacity not released).
NASH (nonalcoholic steatohepatitis)
Phase 2 data released March 29, 2018 - primary endpoint not met.
Methamphetamine dependence
Phase 1b/2a abstract presented at AAN Meeting April 27, 2018.
Amyotrophic lateral sclerosis (ALS)

Latest News

  1. MNOV: Encouraging Data from Subgroup Analysis of ALS Study
  2. MediciNova Announces Clinical Data from Subgroup Analyses of Completed Clinical Trial of MN-166 (ibudilast) in ALS
  3. MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of Hypertriglyceridemia and Hypercholesterolemia in Japan
  4. Detailed Research: Economic Perspectives on Galapagos NV, Cellectis S.A, MediciNova, Logitech International S.A, The Descartes Systems Group, and Canadian Pacific Railway — What Drives Growth in Today's Competitive Landscape
  5. When Will MediciNova Inc (NASDAQ:MNOV) Become Profitable?
  6. Want To Invest In MediciNova Inc (NASDAQ:MNOV)? Here’s How It Performed Lately
  7. MediciNova Announces Opening of Investigational New Drug Application for MN-166 (ibudilast) in Glioblastoma
  8. MediciNova to Present at the UBS Global Healthcare Conference in New York
  9. MediciNova Announces Plans to Collaborate with UCLA Researchers in Grant-Funded Clinical Trial of MN-166 (ibudilast) in Alcohol Use Disorder and Withdrawal
  10. MNOV: Additional Data Presented for MN-166 in MS and ALS
  11. MediciNova Announces Additional Data from Completed Clinical Trial of MN-166 (ibudilast) in ALS Presented at the American Academy of Neurology (AAN) 70th Annual Meeting
  12. MediciNova Announces the Presentation of the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS at the American Academy of Neurology (AAN) 70th Annual Meeting Plenary Session with Additional Imaging Data
  13. Benzinga Pro's 5 Stocks To Watch Today
  14. The Week Ahead In Biotech: PDUFA Dates, IPOs And More
  15. Wired News – MediciNova Released Results of Phase-2 Clinical Trial Assessing MN-166 (ibudilast) in Methamphetamine Dependence
  16. Why Limelight Networks, MediciNova, and Commvault Systems Jumped Today
  17. Here's Why MediciNova Jumped as Much as 26.2% Today